Get the Stockscreener App
2.47
7.49%
-0.20
After Hours:
2.71
0.24
+9.72%
Lisata Therapeutics Inc stock is traded at $2.47, with a volume of 1.60M.
It is down -7.49% in the last 24 hours and down -1.98% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$2.67
Open:
$2.54
24h Volume:
1.60M
Relative Volume:
25.93
Market Cap:
$21.63M
Revenue:
-
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.9841
EPS:
-2.51
Net Cash Flow:
$-18.90M
1W Performance:
-11.15%
1M Performance:
-1.98%
6M Performance:
+2.49%
1Y Performance:
-15.12%
1-Day Range:
$2.4303
$2.6053
1-Week Range:
$2.4303
$2.98
52-Week Range:
$1.87
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.47 | 23.38M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Lisata Therapeutics reports preclinical data showing certepetide’s potential to enhance cancer drug delivery - Proactive financial news
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - The Manila Times
Lisata (Nasdaq: LSTA) cites ADC results: certepetide improved penetration and efficacy - Stock Titan
Can you recover from losses in Lisata Therapeutics Inc.Weekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Is Lisata Therapeutics Inc. reversing from oversold territoryTreasury Yields & Weekly Chart Analysis and Trade Guides - newser.com
Is Lisata Therapeutics Inc. (8NE) stock cheap vs fundamentalsJuly 2025 Market Mood & Breakout Confirmation Alerts - newser.com
Automated trading signals detected on Lisata Therapeutics Inc.Rate Hike & Reliable Price Breakout Signals - newser.com
Why Lisata Therapeutics Inc. stock is recommended by analystsMarket Volume Report & Weekly Chart Analysis and Trade Guides - newser.com
Can Lisata Therapeutics Inc. stock weather global recessionJuly 2025 Trends & Risk Controlled Daily Trade Plans - newser.com
Will Lisata Therapeutics Inc. stock benefit from green energy trendsIndex Update & Accurate Entry/Exit Alerts - newser.com
Smart tools for monitoring Lisata Therapeutics Inc.’s price actionTrade Risk Assessment & Long Hold Capital Preservation Plans - newser.com
Using Bollinger Bands to evaluate Lisata Therapeutics Inc.Take Profit & Verified Entry Point Signals - newser.com
Lisata falls after mid-stage data for anticancer agent - MSN
Why Lisata Therapeutics Inc. stock is rated strong buyMarket Growth Report & Fast Momentum Stock Entry Tips - newser.com
How Lisata Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Entry and Exit Point Strategies - newser.com
Is now a turning point for Lisata Therapeutics Inc.Stop Loss & Weekly Sector Rotation Insights - newser.com
Developing predictive dashboards with Lisata Therapeutics Inc. dataJuly 2025 Selloffs & Safe Entry Momentum Tips - newser.com
What the charts say about Lisata Therapeutics Inc. today2025 Dividend Review & Weekly Setup with ROI Potential - newser.com
How institutional ownership impacts Lisata Therapeutics Inc. stockPortfolio Value Summary & Stepwise Swing Trade Plans - newser.com
Candlestick signals on Lisata Therapeutics Inc. stock todayTrade Entry Summary & High Yield Equity Trading Tips - newser.com
Why institutional investors increase stakes in Lisata Therapeutics Inc. (8NE) stockWeekly Volume Report & Community Shared Stock Ideas - newser.com
Key metrics from Lisata Therapeutics Inc.’s quarterly data2025 Historical Comparison & Entry Point Strategy Guides - newser.com
How sentiment analysis helps forecast Lisata Therapeutics Inc.July 2025 Drop Watch & Growth Focused Stock Reports - newser.com
Custom strategy builders for tracking Lisata Therapeutics Inc.Oil Prices & Capital Efficient Trading Techniques - newser.com
Can Lisata Therapeutics Inc. stock continue upward trend2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
Applying chart zones and confluence areas to Lisata Therapeutics Inc.Weekly Market Report & Safe Capital Growth Tips - newser.com
Is Lisata Therapeutics Inc. stock reversal real or fakeJuly 2025 Market Mood & Long-Term Safe Investment Ideas - newser.com
Will earnings trigger a reversal in Lisata Therapeutics Inc.2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Why Lisata Therapeutics Inc. (8NE) stock fits value portfoliosJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know - MSN
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):